CTX Trademark

Trademark Overview


On Monday, April 16, 2018, a trademark application was filed for CTX with the United States Patent and Trademark Office. The USPTO has given the CTX trademark a serial number of 87878032. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Wednesday, January 1, 2025. This trademark is owned by Cingulate Therapeutics LLC. The CTX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)
ctx

General Information


Serial Number87878032
Word MarkCTX
Filing DateMonday, April 16, 2018
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateWednesday, January 1, 2025
Registration Number5778925
Registration DateTuesday, June 18, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 2, 2019

Trademark Statements


Goods and ServicesResearch and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 23, 2018
Primary Code042
First Use Anywhere DateSunday, June 1, 2014
First Use In Commerce DateSunday, June 1, 2014

Trademark Owner History


Party NameCingulate Therapeutics LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressKansas City, KS 66205

Party NameCingulate Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressKansas City, KS 66205

Party NameCingulate Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressKansas City, KS 66205

Trademark Events


Event DateEvent Description
Thursday, April 19, 2018NEW APPLICATION ENTERED
Monday, April 23, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 4, 2018ASSIGNED TO EXAMINER
Monday, August 13, 2018NON-FINAL ACTION WRITTEN
Monday, August 13, 2018NON-FINAL ACTION E-MAILED
Monday, August 13, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 31, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 31, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 31, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 6, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 22, 2019ASSIGNED TO LIE
Wednesday, March 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 2, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 18, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, July 20, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 20, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 20, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 18, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, August 1, 2024TEAS SECTION 8 & 15 RECEIVED
Wednesday, January 1, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, January 1, 2025REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, January 1, 2025NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED